Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.
The user had a hair transplant 5 years ago and is currently using 1 mg finasteride and topical minoxidil but is not seeing an increase in hair volume. They are considering another transplant to improve hair volume.
The user has high DHT levels despite using dutasteride, which may not be effective due to potential damage or spoilage. They are considering a hair transplant if DHT levels don't decrease after two years.
Breezula's effectiveness is uncertain, with some users skeptical about its potential and others noting its recent availability on the grey market. A user reported success with a stack of Dutasteride (oral), Minoxidil (topical), and RU58841 (topical), achieving significant hair improvement after 18 months.
New hair loss treatments like VDPHL01, PP405, Gt20029, and Breezula are anticipated, with VDPHL01 possibly releasing in 2027/28. Current treatments include finasteride, dutasteride, and minoxidil, but new options are eagerly awaited.
The conversation discusses using oral spironolactone for hair loss in males when 5ari blockers fail. Concerns are raised about spironolactone's side effects, and alternatives like pyrilutamide and breezula are suggested.
A 20-year-old male experiencing hair loss is using topical finasteride and recently added dutasteride but is still losing hair and considering giving up. Suggestions include being patient, giving dutasteride more time, trying oral finasteride, adding minoxidil, and considering other treatments like low-level laser therapy.
A user shared their 1 year and 5 months update on using finasteride and minoxidil for hair loss, noting improved hair density but a still receding hairline. They mentioned being inconsistent with minoxidil initially and experiencing more hair shedding after starting it.
The conversation is about a user's progress with hair regrowth after using minoxidil for three months. Many suggest adding finasteride to maintain results, and the user also uses ketoconazole shampoo for dandruff.
The user has been experiencing continuous hair loss despite using finasteride, minoxidil, and dermastamping. They are seeking advice on what to do next.
The conversation is about finding a source for RU58841 in Canada as an additional treatment for hair loss, alongside oral minoxidil and dutasteride. Alternatives like kx826 are suggested, with some users discussing prices and sources for these products.
The conversation discusses using RU58841 with primobolan or masteron to protect hair while on steroids, alongside dutasteride. Users suggest caution with these compounds due to potential hair loss and discuss alternatives like nandrolone and EQ for better hair safety.
The user switched from finasteride to 1mg dutasteride daily due to continued hair loss and is also using minoxidil and rosemary oil. They are seeking advice on whether to increase the dutasteride dosage for better regrowth.
Switching from finasteride to dutasteride can cause initial shedding, but many see long-term hair regrowth and stabilization. Responses vary, with some experiencing fewer side effects and others finding it less effective.
Hair loss can be caused by various factors such as stress, thyroid issues, and genetics. Treatments mentioned include dutasteride, DHT blockers, and thyroid medication, though results vary.
KX-826 is undergoing trials for hair loss treatment, showing similar effectiveness between 0.5% and 1.0% dosages, with mild side effects compared to finasteride. Users discuss combining KX-826 with other treatments like minoxidil and clascoterone for better results.
PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.
Young people are using hair loss treatments like finasteride and dutasteride without having hair loss, influenced by social media trends. Concerns are raised about the potential long-term effects of taking these medications at a young age.
Testosterone can still cause hair loss even when DHT is blocked by dutasteride, especially if hair follicles are sensitive. Topical treatments like RU58841 or pyrilutamide may help, but their long-term effectiveness is uncertain compared to dutasteride.
The conversation discusses alternative and unorthodox hair loss treatments, including RU58841, nandrolone, and dianabol, as well as theoretical approaches involving high doses of estrogen and selective estrogen receptor modulators. These methods are considered extreme and potentially harmful but are explored for those unable to tolerate traditional 5-alpha reductase inhibitors.
A new hair loss protocol using FDA-approved topical treatments targets eight pathways, potentially improving results by 60-75% compared to the standard 40-50% from oral minoxidil and finasteride. The protocol includes minoxidil, finasteride, tacrolimus, cetirizine, bimatoprost, lithium gluconate, losartan, melatonin, NAC, caffeine, and tretinoin, with a monthly cost of $35-50 in Mexico and $80-150 in the US.
A transgender woman experienced significant hair regrowth after 18 months of hormone replacement therapy (HRT) with estrogen and bicalutamide. The discussion notes HRT's effectiveness for hair regrowth but warns against its use for cisgender men due to feminizing effects.
Using estrogen for hair regrowth is considered ineffective and risky, with potential side effects like breast growth and hormonal changes. Alternatives like finasteride, dutasteride, and minoxidil are suggested, but estrogen is not recommended unless transitioning.
The conversation discusses various hair loss treatments, including minoxidil, finasteride, dutasteride, pyrilutamide, alfatrodial, and nizoral, with a focus on the potential of new treatments like gt20029 and breezula. There is optimism about novel treatments that don't have systemic effects, although skepticism remains about the effectiveness of some new drugs.
Hair loss treatments like Minoxidil, finasteride, and RU58841, focusing on their effectiveness and side effects. It also highlights the disparity in medical research funding between hair loss and conditions like endometriosis.
Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.